stoxline Quote Chart Rank Option Currency Glossary
  
Inhibrx Biosciences, Inc. (INBX)
12.85  -0.22 (-1.68%)    02-19 13:48
Open: 12.8
High: 13.1695
Volume: 15,844
  
Pre. Close: 13.07
Low: 12.63
Market Cap: 186(M)
Technical analysis
2025-02-19 1:20:51 PM
Short term     
Mid term     
Targets 6-month :  15.98 1-year :  17.35
Resists First :  13.68 Second :  14.85
Pivot price 12.96
Supports First :  11.78 Second :  9.8
MAs MA(5) :  13.02 MA(20) :  12.94
MA(100) :  14.69 MA(250) :  20.14
MACD MACD :  -0.3 Signal :  -0.4
%K %D K(14,3) :  56.3 D(3) :  58.3
RSI RSI(14): 43.8
52-week High :  39.79 Low :  10.8
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ INBX ] has closed above bottom band by 33.6%. Bollinger Bands are 34.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 13.55 - 13.62 13.62 - 13.68
Low: 12.71 - 12.78 12.78 - 12.83
Close: 12.96 - 13.08 13.08 - 13.17
Company Description

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.

Headline News

Wed, 05 Feb 2025
BlackRock, Inc. Increases Stake in Inhibrx Biosciences Inc. - GuruFocus.com

Tue, 21 Jan 2025
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer – Company Announcement - Financial Times

Tue, 21 Jan 2025
Inhibrx's Ozekibart Shows Promising 40% Response Rate in Advanced Colorectal Cancer Trial - StockTitan

Mon, 13 Jan 2025
Inhibrx Secures $150M Financing Deal to Advance Clinical Programs, Receives $100M Upfront - StockTitan

Mon, 13 Jan 2025
Inhibrx Biosciences Announces Loan Agreement with Oxford Finance - PR Newswire

Thu, 14 Nov 2024
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 0 (M)
Held by Insiders 1.448e+007 (%)
Held by Institutions 7.6e+006 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.8939e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 119.38
Profit Margin 110 %
Operating Margin 218.7 %
Return on Assets (ttm) -19 %
Return on Equity (ttm) 345.3 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 172.36
Sales Per Share -165.04
EBITDA (p.s.) 0
Qtrly Earnings Growth -3.0144e+008 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0.1
Price to Sales -0.08
Price to Cash Flow 0
Stock Dividends
Dividend 1.22e+006
Forward Dividend 1.25e+006
Dividend Yield 9606300%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android